Quality in Acute Stroke Care (QASC) Germany : improving efficiency in stroke care with nurseinitiated FeSS-protocols

Background: Nurse-initiated supported implementation of protocols to manage fever, hyperglycaemia (sugar) and
swallowing (FeSS) following acute stroke reduced 90-day death and disability in the landmark Australian Quality
in Acute Stroke Care (QASC)-Trial. An international interprofessional collaboration sought to evaluate the effects of nurse-led FeSS implementation on FeSS Protocol adherence in German stroke units.
Methods: This pre-test/post-test study was conducted in eight German stroke units between 2020 and 2022. Stroke
nurses as clinical champions, supported by the project team, conducted multidisciplinary workshops discussing
pre-implementation medical record audit results, barriers and facilitators to FeSS Protocol implementation, developed
action plans and provided education, with ongoing support from Australia. Medical record audit data were collected
by nurses, pre-implementation and three months post-implementation.
Results: In 771 (pre-implementation) and 679 (post-implementation) patients there were improvements in overall
FeSS adherence (pre 20%, post 28%; adjusted difference in proportions (95% CI) 11%, (5.1%, 16%); p < 0.001),
adherence to hyperglycaemia (pre 43%, post 55%; adjusted difference 23%, (17%, 29%); p < 0.001) and swallowing (pre
52%, post 61%; adjusted difference 11%, (5.2%, 17%); p < 0.001) but not fever protocol (pre 76%, post 78%; adjusted
difference 1.5%, (-2.6%, 5.7%); p = 0.474). Improvements also were noted in administration of anti-pyretics (pre 29%,
post 59%; adjusted difference 32%, (20%, 44%); p < 0.001); and insulin (pre 41%, post 60%; adjusted difference 14%,
(1.1%, 28%); p < 0.034) both within one hour, as well as in performing a swallow screen within 24 h of admission (pre
65%, post 74%; adjusted difference 18% (8.8%, 26%); p < 0.001).
Conclusions: Supported implementation of the FeSS Protocols significantly improved acute care for post stroke
complications of fever, hyperglycaemia and dysphagia in terms of higher adherence and shorter time to treatment.
Trial registration: As this is a pre-test/post-test study and does not meet the WHO/ICMJE definition of a clinical trial,
registration was not required.

© The Author(s) 2024.

Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.